Limits...
The association, clinicopathological significance, and diagnostic value of CDH1 promoter methylation in head and neck squamous cell carcinoma: a meta-analysis of 23 studies

View Article: PubMed Central - PubMed

ABSTRACT

Epithelial cadherin (encoded by the CDH1 gene) is a tumor suppressor glycoprotein that plays a role in the invasion and metastasis of human cancers. As previous studies regarding the association between CDH1 promoter methylation and head and neck squamous cell carcinoma (HNSCC) have yielded inconsistent conclusions, a meta-analysis was performed. A systematic literature review was undertaken from four databases: PubMed, Embase, Google Scholar, and Web of Science. Finally, a total of 23 studies (including 1,727 cases of HNSCC and 555 normal controls) were included in the present study. Our results showed that the frequency of CDH1 promoter methylation in HNSCC was statistically greater than in controls (odds ratio [OR] =5.94, 95% confidence interval [CI]: 3.36–10.51, P<0.001). In reported cases of HNSCC, CDH1 promoter methylation was statistically associated with tumor stage (OR =0.46, 95% CI: 0.27–0.78, P=0.004) and a history of alcohol consumption (OR =6.04, 95% CI: 2.41–15.14, P<0.001). Moreover, the sensitivity, specificity, and area under the curve of the summary receiver operator characteristic for the included studies were 0.50 (95% CI: 0.4–0.61), 0.89 (95% CI: 0.79–0.95), and 0.74 (95% CI: 0.70–0.78), respectively. In conclusion, our meta-analyses indicated that CDH1 promoter methylation was associated with HNSCC risk, and may be utilized as a valuable diagnostic biomarker for HNSCC.

No MeSH data available.


Related in: MedlinePlus

SROC plot with best-fitting asymmetric curve of methylated CDH1 for the diagnosis of HNSCC.Abbreviations: AUC, area under curve; HNSCC, head and neck squamous cell carcinoma; SENS, sensitivity; SPEC, specificity; SROC, summary of receiver operating characteristic.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5096767&req=5

f8-ott-9-6763: SROC plot with best-fitting asymmetric curve of methylated CDH1 for the diagnosis of HNSCC.Abbreviations: AUC, area under curve; HNSCC, head and neck squamous cell carcinoma; SENS, sensitivity; SPEC, specificity; SROC, summary of receiver operating characteristic.

Mentions: In the current analysis, 17 eligible case–control studies were included to assess the diagnostic value of CDH1 promoter methylation for HNSCC. Figure 7 shows the pooled sensitivity and specificity for all included studies, which were 0.50 (95% CI: 0.40–0.61) and 0.89 (95% CI: 0.79–0.95). The AUC of the summary ROC was 0.74 (95% CI: 0.70–0.78) (Figure 8), indicating that the detection of CDH1 methylation was associated with a diagnosis of HNSCC, representing a potential diagnostic biomarker.


The association, clinicopathological significance, and diagnostic value of CDH1 promoter methylation in head and neck squamous cell carcinoma: a meta-analysis of 23 studies
SROC plot with best-fitting asymmetric curve of methylated CDH1 for the diagnosis of HNSCC.Abbreviations: AUC, area under curve; HNSCC, head and neck squamous cell carcinoma; SENS, sensitivity; SPEC, specificity; SROC, summary of receiver operating characteristic.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5096767&req=5

f8-ott-9-6763: SROC plot with best-fitting asymmetric curve of methylated CDH1 for the diagnosis of HNSCC.Abbreviations: AUC, area under curve; HNSCC, head and neck squamous cell carcinoma; SENS, sensitivity; SPEC, specificity; SROC, summary of receiver operating characteristic.
Mentions: In the current analysis, 17 eligible case–control studies were included to assess the diagnostic value of CDH1 promoter methylation for HNSCC. Figure 7 shows the pooled sensitivity and specificity for all included studies, which were 0.50 (95% CI: 0.40–0.61) and 0.89 (95% CI: 0.79–0.95). The AUC of the summary ROC was 0.74 (95% CI: 0.70–0.78) (Figure 8), indicating that the detection of CDH1 methylation was associated with a diagnosis of HNSCC, representing a potential diagnostic biomarker.

View Article: PubMed Central - PubMed

ABSTRACT

Epithelial cadherin (encoded by the CDH1 gene) is a tumor suppressor glycoprotein that plays a role in the invasion and metastasis of human cancers. As previous studies regarding the association between CDH1 promoter methylation and head and neck squamous cell carcinoma (HNSCC) have yielded inconsistent conclusions, a meta-analysis was performed. A systematic literature review was undertaken from four databases: PubMed, Embase, Google Scholar, and Web of Science. Finally, a total of 23 studies (including 1,727 cases of HNSCC and 555 normal controls) were included in the present study. Our results showed that the frequency of CDH1 promoter methylation in HNSCC was statistically greater than in controls (odds ratio [OR] =5.94, 95% confidence interval [CI]: 3.36–10.51, P<0.001). In reported cases of HNSCC, CDH1 promoter methylation was statistically associated with tumor stage (OR =0.46, 95% CI: 0.27–0.78, P=0.004) and a history of alcohol consumption (OR =6.04, 95% CI: 2.41–15.14, P<0.001). Moreover, the sensitivity, specificity, and area under the curve of the summary receiver operator characteristic for the included studies were 0.50 (95% CI: 0.4–0.61), 0.89 (95% CI: 0.79–0.95), and 0.74 (95% CI: 0.70–0.78), respectively. In conclusion, our meta-analyses indicated that CDH1 promoter methylation was associated with HNSCC risk, and may be utilized as a valuable diagnostic biomarker for HNSCC.

No MeSH data available.


Related in: MedlinePlus